torrent pharmaceuticals ltd l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Torrent Pharmaceuticals Ltd PowerPoint Presentation
Download Presentation
Torrent Pharmaceuticals Ltd

Loading in 2 Seconds...

play fullscreen
1 / 21

Torrent Pharmaceuticals Ltd - PowerPoint PPT Presentation


  • 105 Views
  • Uploaded on

Torrent Pharmaceuticals Ltd. Investor Presentation Q1 FY 2012. Caveat.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Torrent Pharmaceuticals Ltd' - ivi


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
torrent pharmaceuticals ltd

Torrent Pharmaceuticals Ltd

Investor Presentation Q1 FY 2012

slide2

Caveat

This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/ details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section before taking any action with regard to their own specific objectives. Further, the discussion following herein reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company undertakes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.

slide3

Contents

  • Performance Highlights
  • Financials
  • Business Segments
    • India
    • International
  • Facilities – Expansion Plan
q1 fy12 highlights
Q1 FY12 Highlights
  • Revenues at Rs. 6,475 Mn vs. Rs 5,410 Mn
      • Revenue growth of 20% on the back of growth from US, Brazil and Contract manufacturing operations.
    • Non recurring income of Rs. 170 Mn towards dossier out licensing income
  • PAT grows by 38% at Rs. 1,025 Mn vs. Rs 742 Mn
      • Lower margins in Indian formulations business due to higher manufacturing overheads.
slide7
P&L

Rs. Mn

slide10

India

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
    • Lower revenue growth on account of lower growth in gastro and pain therapies
    • Lower margins on account of higher manufacturing overheads
  • Growth drivers
    • Consolidate entry into newer geographies and therapeutic areas
    • Brand building thru increased Specialty Coverage & Creeping Expansion in Customer Base
    • New Product Introductions including filling of Portfolio Gaps
    • Entry into new therapeutic areas
slide12

International Operations – Expanding Share

FY 11 - Turnover

Growing share of International – up from 26% to 51%

International Revenues

Rs. Mn

slide13

Brazil

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
    • Reai growth of ~ 10% with volumes growing 1%, New Introductions 14%, Price de-growth 5%.
    • Adjusted for sales spill over in Q4 LY, sales in Reai de-grew by 16%
    • Torrent growing at 8% vs. Covered Market growth of 9%
  • Growth Drivers
    • Existing Products & Introduction of new products (30-35 new launches by 2014-15)
slide14

Mexico

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
    • Actively marketing 4 molecules in CNS
    • 2 new products lined up for launch in CNS for the year
    • Field force of 30 people covering 70% of Mexican market.
  • Growth Drivers
    • Entry into CV segment deferred for next year
    • Portfolio to grow to 30 products in 4 years with field force of 200 people
slide15

USA

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
    • Launched 2 new molecules in Q1 taking total number of molecules to 17 actively marketed
    • Improved margins on account of higher revenues
    • 28 ANDA's approved till date (17 actively marketed, 4 under patent)
  • Growth Drivers
    • 32 ANDA's pending for approval & 22 ANDA's under development
    • Break-even likely by 2012-13
slide16

Germany - Heumann

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
    • Euro sales growth of 8%, with continuous improvement in market share over last 4 quarters
    • Stable margins
  • Growth Drivers
    • Heumann successful in winning tenders
    • New Products going off patent and Therapy coverage expansion
    • Shift of manufacturing base to India to boost competitiveness in bidding
slide17

Europe (excl Heumann)

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY 12 Highlights
  • Sales growth affected by lower sales contribution from new product introductions
    • 2 new products launched during the quarter
  • Growth Drivers
  • New Product Pipeline – 30 products till 2014-15
  • Increasing geographical reach through direct field force presence in Romania and UK in the immediate term.
slide18

ROW

Highlights & Growth Drivers

Rs. Mn

  • Q1 FY12 Highlights
    • Top line growth of 19%, adjusted for currency movements top line grew by 22%
  • Growth Drivers
    • Entry into semi-regulated markets like Thailand (Market Size of over USD 2 bio) – Revenues expected to flow from FY13.
    • Increased focus on existing territories with direct field force presence viz. Philippines, Sri Lanka, Vietnam & Myanmar
    • Scale up of operations in regulated markets like Australia & semi-regulated markets like South Africa.
    • Minimize development costs by leveraging on R&D costs incurred for developed markets
slide20

Facilities – Expansion Plan

  • Dahej SEZ
  • Nature: Formulation & API Capacity Enhancement
  • Project Cost: Rs. 800 crores
  • Planned capacities: 50 TPA plus 11,000 million tablets / capsules p.a.
  • Timelines for completion:
    • Phase I: Project cost of Rs. 500 crores, commissioning in FY 2014-15
    • Phase II: Project cost of Rs. 300 crores, commissioning in FY 2016-17
  • Justification:
    • With growing volumes in US / EU, API + Formulation capacity constraint is anticipated 2-3 years.